K. Otani

1.6k total citations
49 papers, 1.1k citations indexed

About

K. Otani is a scholar working on Psychiatry and Mental health, Pharmacology and Pharmacology. According to data from OpenAlex, K. Otani has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 11 papers in Pharmacology and 10 papers in Pharmacology. Recurrent topics in K. Otani's work include Schizophrenia research and treatment (13 papers), Bipolar Disorder and Treatment (11 papers) and Pharmacogenetics and Drug Metabolism (10 papers). K. Otani is often cited by papers focused on Schizophrenia research and treatment (13 papers), Bipolar Disorder and Treatment (11 papers) and Pharmacogenetics and Drug Metabolism (10 papers). K. Otani collaborates with scholars based in Japan, United States and Sweden. K. Otani's co-authors include Shuji Kaneko, Akihito Suzuki, Y. Fukushima, Tsuyoshi Kondo, Tomoko Hirano, Kazuo Mihara, Takashi Fukasawa, Motohiro Okada, M. Ishida and K. Sugawara and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Psychiatry and PLANT PHYSIOLOGY.

In The Last Decade

K. Otani

49 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Otani Japan 18 432 279 274 257 251 49 1.1k
P. R. Bieck Germany 19 225 0.5× 320 1.1× 238 0.9× 165 0.6× 310 1.2× 73 1.2k
K. H. Antonin Germany 16 261 0.6× 226 0.8× 135 0.5× 142 0.6× 203 0.8× 36 954
Wen‐Ho Chang Taiwan 22 1.1k 2.5× 467 1.7× 248 0.9× 318 1.2× 231 0.9× 37 1.8k
David Critchley United Kingdom 16 274 0.6× 531 1.9× 447 1.6× 155 0.6× 267 1.1× 24 1.2k
I. W. Reimann Germany 19 247 0.6× 153 0.5× 205 0.7× 295 1.1× 307 1.2× 41 1.2k
Holly R. Thomasson United States 22 192 0.4× 289 1.0× 446 1.6× 204 0.8× 311 1.2× 29 2.2k
Bo Siwers Sweden 17 292 0.7× 228 0.8× 192 0.7× 170 0.7× 256 1.0× 23 865
Mary Pat Knadler United States 22 334 0.8× 132 0.5× 204 0.7× 371 1.4× 602 2.4× 44 1.5k
Manickam Aravagiri United States 23 1.0k 2.4× 376 1.3× 359 1.3× 158 0.6× 272 1.1× 50 1.8k
K. Fredricson Overø Denmark 18 561 1.3× 282 1.0× 158 0.6× 322 1.3× 611 2.4× 39 1.4k

Countries citing papers authored by K. Otani

Since Specialization
Citations

This map shows the geographic impact of K. Otani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Otani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Otani more than expected).

Fields of papers citing papers by K. Otani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Otani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Otani. The network helps show where K. Otani may publish in the future.

Co-authorship network of co-authors of K. Otani

This figure shows the co-authorship network connecting the top 25 collaborators of K. Otani. A scholar is included among the top collaborators of K. Otani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Otani. K. Otani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Suzuki, Akihito, et al.. (2020). Interrelation Between Increased BDNF Gene Methylation and High Sociotropy, a Personality Vulnerability Factor in Cognitive Model of Depression. SHILAP Revista de lepidopterología. 1 indexed citations
2.
Fukasawa, Takashi, Akihito Suzuki, & K. Otani. (2007). Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. Journal of Clinical Pharmacy and Therapeutics. 32(4). 333–341. 82 indexed citations
3.
Miura, Masatomo, K. Otani, & Takayoshi Ohkubo. (2005). Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 35(5). 455–465. 11 indexed citations
4.
Fukasawa, Takashi, Norio Yasui‐Furukori, Akihito Suzuki, et al.. (2005). Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. European Journal of Clinical Pharmacology. 61(11). 791–795. 25 indexed citations
5.
Yasui‐Furukori, Norio, Takashi Fukasawa, Toshiaki Aoshima, et al.. (2004). Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. European Journal of Clinical Pharmacology. 60(6). 427–30. 32 indexed citations
6.
Yasui‐Furukori, Norio, Tsuyoshi Kondo, Takeshi Kubota, et al.. (2001). No correlations between the urinary ratio of 6β-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. European Journal of Clinical Pharmacology. 57(4). 285–288. 10 indexed citations
7.
Suzuki, Akihito, Tsuyoshi Kondo, Kazuo Mihara, et al.. (2001). Association between Taq I A dopamine D 2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report. European Archives of Psychiatry and Clinical Neuroscience. 251(2). 57–59. 21 indexed citations
8.
Mihara, Kazuo, K. Otani, N. Yasui, et al.. (1999). No Pharmacokinetic but Pharmacodynamic Interactions Between Cisapride and Bromperidol or Haloperidol. Therapeutic Drug Monitoring. 21(3). 297–297. 2 indexed citations
9.
Yasui, N., Toshikazu Kondo, Akihito Suzuki, et al.. (1999). Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. International Clinical Psychopharmacology. 14(2). 113–118. 8 indexed citations
10.
11.
Mihara, Kazuo, K. Otani, Akihito Suzuki, et al.. (1997). Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m -chlorophenylpiperazine. Psychopharmacology. 133(1). 95–98. 30 indexed citations
12.
Otani, K., M. Ishida, N. Yasui, et al.. (1997). Interaction between carbamazepine and bromperidol. European Journal of Clinical Pharmacology. 52(3). 219–222. 16 indexed citations
13.
Otani, K., Tsuyoshi Kondo, M. Ishida, et al.. (1996). Plasma prolactin concentration and psychopathology of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 20(8). 1369–1374. 6 indexed citations
14.
Tanaka, Osamu, et al.. (1996). A Method for Rapid Determination of Zotepine by Gas Chromatography-Mass Spectrometry. Therapeutic Drug Monitoring. 18(3). 294–296. 9 indexed citations
15.
Otani, K., M. Ishida, Shuji Kaneko, et al.. (1996). Effects of Carbamazepine Coadministration on Plasma Concentrations of Trazodone and Its Active Metabolite, m-Chlorophenylpiperazine. Therapeutic Drug Monitoring. 18(2). 164–167. 26 indexed citations
16.
Okada, Motohiro, Shuji Kaneko, Tomoko Hirano, et al.. (1995). Effects of zonisamide on dopaminergic system. Epilepsy Research. 22(3). 193–205. 145 indexed citations
17.
Otani, K., N. Yasui, Shuji Kaneko, et al.. (1995). Trazodone treatment increases plasma prolactin concentrations in depressed patients. International Clinical Psychopharmacology. 10(2). 115–118. 15 indexed citations
18.
19.
Otani, K., Tomoko Hirano, Tsuyoshi Kondo, et al.. (1990). Biperiden and Piroheptine Do Not Affect the Serum Level of Zotepine, a New Antipsychotic Drug. The British Journal of Psychiatry. 157(1). 128–130. 13 indexed citations
20.
Otani, K., et al.. (1989). Hepatic injury caused by mianserin.. BMJ. 299(6697). 519.2–519. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. R. Bieck Breakdown of academic impact, for papers by K. H. Antonin Breakdown of academic impact, for papers by Wen‐Ho Chang Breakdown of academic impact, for papers by David Critchley Breakdown of academic impact, for papers by I. W. Reimann Breakdown of academic impact, for papers by Holly R. Thomasson Breakdown of academic impact, for papers by Bo Siwers Breakdown of academic impact, for papers by Mary Pat Knadler Breakdown of academic impact, for papers by Manickam Aravagiri Breakdown of academic impact, for papers by K. Fredricson Overø
Rankless by CCL
2026